MannKind reported 201.15 in PE Price to Earnings for its fiscal quarter ending in March of 2026.





Pe Change Date
Adma Biologics 15.02 14.71 Mar/2026
BioCryst Pharmaceuticals 6.84 0.78 Jun/2026
Eli Lilly 32.9 7.37 Jun/2026
Halozyme Therapeutics 12.51 1.15 Jun/2026
MannKind 201.15 102.55 Mar/2026
Merck 32.26 15.74 Jun/2026
Novavax 2.01 1.07 Dec/2025
Novo Nordisk 9.94 0.47 Jun/2026
Pfizer 11.48 2.16 Jun/2026
Sanofi 18.96 7.12 Jun/2026
Xencor 29.92 3.22 Sep/2022